Lexaria Provides Update On Investigational New Drug Application Progress With The FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Designated As HYPER-H23-1
Portfolio Pulse from Happy Mohamed
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has provided an update on its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its planned U.S. Phase 1b Hypertension Clinical Trial. The company has completed work under its control, but the submission of the IND package to the FDA has been delayed due to the lack of required documentation from one of Lexaria's material suppliers.
August 30, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lexaria's IND application delay could potentially impact the company's stock negatively in the short term.
The delay in the IND application could potentially lead to a delay in the clinical trial, which could negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
The delay in Lexaria's IND application could potentially impact the company's stock negatively in the short term.
The delay in the IND application could potentially lead to a delay in the clinical trial, which could negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100